Navigation Links
Benefit of cancer prevention surgery differs between women with BRCA1 and BRCA2 mutations
Date:2/11/2008

The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) is the first prospective examination of the impact of this procedure in which BRCA2 mutation carriers were analyzed separately from BRCA1 mutation carriers. All previous studies evaluating this approach have only examined BRCA1 and BRCA2 mutation carriers together or have limited their analysis to BRCA1 mutation carriers alone.

The findings of the new study, to be published in the March 2008 issue of the Journal of Clinical Oncology, may have important implications for women comparing the risks and benefits of specific cancer-risk-reduction options.

According to the research, the surgery called risk-reducing salpingo-oophorectomy (RRSO) may confer different benefits for women at inherited risk for breast and ovarian cancer depending upon whether BRCA1 or BRCA2 is abnormal. The efficacy of this procedure for the prevention of breast and gynecologic cancer had never been evaluated in groups of women stratified according to mutation type, despite 17 percent to 39 percent of all BRCA mutation carriers having a mutation in the BRCA2 gene.

These findings will allow doctors to better tailor risk-reduction approaches for women at inherited risk for breast and ovarian cancer, said the studys lead author, Noah Kauff, MD, a gynecologist and geneticist at MSKCC. Given these results, further studies evaluating the efficacy of risk-reduction strategies in BRCA mutation carriers will likely need to stratify by the specific gene mutated, he added.

Researchers compared the incidence of breast and gynecologic cancers between a group of 509 women 30 years of age or older who carried a BRCA1 or BRCA2 mutation and had undergone RRSO, and a group of 283 women with these mutations who did not have the surgery. The women were followed prospectively for three years via questionnaire and medical record review.

Investigators found that RRSO was associated with a 72 percent breast cancer risk reduction in women with BRCA2 mutations nearly twice the reduction in breast cancer risk compared to women with BRCA1 mutations. The surgery also reduced the risk of gynecologic cancer by 85 percent in women with a BRCA1 mutation. While protection against gynecologic cancer was suggested in women with a BRCA2 mutation, researchers were not able to estimate the level of reduced risk due to the low incidence of gynecologic cancers among women with these mutations.

Further analyses demonstrated that RRSO appeared to reduce the risk of estrogen receptor (ER)-positive breast cancer by 78 percent in women with a mutation in either BRCA1 or BRCA2, but had no effect on the development of ER-negative breast cancers. Because BRCA1 carriers are more likely to be diagnosed with ER-negative breast cancers, the authors note that carriers of these mutations need to consider additional breast-cancer-risk-reduction strategies, such as intensive screening with breast MRI or prophylactic mastectomy.

While our results suggest that removal of the ovaries in women with BRCA1 or BRCA2 mutations is highly protective against ER-positive breast cancers, further research is urgently needed to develop effective non-surgical prevention strategies for the ER-negative cancers that are frequently associated with these mutations, said Dr. Kauff.


'/>"/>

Contact: Esther Napolitano
napolite@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
3. Discovery of sugar sensor in intestine could benefit diabetes
4. Study shines more light on benefit of vitamin D in fighting cancer
5. Vitamin Es lack of heart benefit linked to dosage
6. Practice-based intervention has sustained benefits for children and families
7. Manic phase of bipolar disorder benefits from breast cancer medication
8. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
9. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
10. The Butterfly Ball to Benefit Lung Association
11. Smaller breast reduction surgeries provide health benefits and should be reimbursed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: